Risk of selecting K65R in anti retroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir

被引：42

作者：

Sheldon, JA ^{[1
]}

Corral, A

Rodés, B

Mauss, S

Rockstroh, J

Berger, F

Schwarze-Zander, C

Soriano, V

机构：

[1] Hosp Carlos III, Dept Infect Dis, Madrid, Spain

[2] Ctr HIV & Hepatogastroenterol, Dusseldorf, Germany

[3] Univ Bonn, Dept Med, D-5300 Bonn, Germany

来源：

AIDS | 2005年 / 19卷 / 17期

关键词：

D O I：

10.1097/01.aids.0000189563.79976.05

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Seven antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir for longer than 6 months were assessed. Using bulk population sequencing and a sensitive limiting dilution analysis, the selection of K65R or other resistance mutations did not occur in HIV, suggesting that adefovir can be confidently used as hepatitis B virus (HBV) therapy in HIV/HBV-co-infected patients who do not require antiretroviral therapy.

引用

收藏

页码：2036 / 2038

页数：3

相关论文

共 15 条

[1] Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study [J].

Benhamou, Y ;

Bochet, M ;

Thibault, V ;

Calvez, V ;

Fievet, MH ;

Vig, P ;

Gibbs, CS ;

Brosgart, C ;

Fry, J ;

Namini, H ;

Katiama, C ;

Poynard, T .

LANCET, 2001, 358 (9283) :718-723

[2] Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro [J].

Cherrington, JM ;

Mulato, AS ;

Fuller, MD ;

Chen, MS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (09) :2212-2216

[3] Human immunodeficiency virus (HIV) type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine [J].

Delaugerre, C ;

Marcelin, AG ;

Thibault, V ;

Peytavin, G ;

Bombled, T ;

Bochet, MV ;

Katlama, C ;

Benhamou, Y ;

Calvez, V .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (05) :1586-1588

[4]

Foli A, 1996, ANTIVIR RES, V32, P91, DOI 10.1016/0166-3542(95)00985-X

[5] K65R MUTATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE ENCODES CROSS-RESISTANCE TO 9-(2-PHOSPHONYLMETHOXYETHYL)ADENINE [J].

GU, ZX ;

SALOMON, H ;

CHERRINGTON, JM ;

MULATO, AS ;

CHEN, MS ;

YARCHOAN, R ;

FOLI, A ;

SOGOCIO, KM ;

WAINBERG, MA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (08) :1888-1891

[6] Efficacy and safety of adefovir dipivoxil with antiretroviral therapy - A randomized controlled trial [J].

Kahn, J ;

Lagakos, S ;

Wulfsohn, M ;

Cherng, D ;

Miller, M ;

Cherrington, J ;

Hardy, D ;

Beall, G ;

Cooper, R ;

Murphy, R ;

Basgoz, N ;

Ng, E ;

Deeks, S ;

Winslow, D ;

Toole, JJ ;

Coakley, D .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (24) :2305-2312

[7] Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort [J].

Konopnicki, D ;

Mocroft, A ;

de Wit, S ;

Antunes, F ;

Ledergerber, B ;

Katlama, C ;

Zilmer, K ;

Vella, S ;

Kirk, O ;

Lundgren, JD .

AIDS, 2005, 19 (06) :593-601

[8]

Miller MD, 2004, AIDS REV, V6, P22

[9] Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro [J].

Miller, MD ;

Anton, KE ;

Mulato, AS ;

Lamy, PD ;

Cherrington, JM .

JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (01) :92-100

[10]

Miller MD, 2001, J ACQ IMMUN DEF SYND, V27, P450, DOI 10.1097/00126334-200108150-00005